Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis

Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into a license agreement with Polyphor Ltd. for POL6014, a clinical stage selective inhibitor of human neutrophil elastase with the potential to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases such as non-cystic fibrosis bronchiectasis (NCFB), alpha-1 antitrypsin deficiency (AATD) and primary ciliary dyskinesia (PCD).

As quoted in the press release:

“With the licensing of POL6014 Santhera is broadening its clinical stage pipeline in rare diseases with the option to address multiple pulmonary indications,” said Thomas Meier, PhD, CEO of Santhera. “There is still a high unmet medical need in treating the chronic inflammation in patients with cystic fibrosis and other neutrophilic pulmonary diseases. In a first step, we intend to execute a multiple ascending dose (MAD) tolerability trial during the second half of 2018 which has already been planned by Polyphor. In parallel, we will initiate discussions with EU and U.S. regulators around the development program for POL6014 in CF and other indications.”

Click here to read the full press release.